Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

RESTATED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)

RESTATED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Pre-funded warrants Common Stock	Pre-funded warrants Additional Paid-In Capital	Pre-funded warrants	Tranche A Warrants Preferred Stock	Tranche A Warrants	Preferred Stock Series E-2 preferred stock	Preferred Stock Series E-3 preferred stock	Preferred Stock	Common Stock Series E-2 preferred stock	Common Stock Series E-3 preferred stock	Common Stock	Additional Paid-In Capital Series E-2 preferred stock	Additional Paid-In Capital Series E-3 preferred stock	Additional Paid-In Capital	Accumulated Deficit	Series D preferred stock	Total
Balance beginning at Dec. 31, 2022											$ 94			$ 168,143,557	$ (159,990,407)		$ 8,153,244
Balance beginning (in shares) at Dec. 31, 2022											9,385,272
Balance beginning Series D preferred stock at Dec. 31, 2022																$ 1,382,023
Balance beginning Series D preferred stock (in shares) at Dec. 31, 2022																111.11
Stock-based compensation														408,206			408,206
Conversion of preferred stock to common stock	$ 3		$ 3
Conversion of preferred stock to common stock (in shares)	355,235
Net loss															(7,190,470)		(7,190,470)
Balance ending Series D preferred stock at Mar. 31, 2023																$ 1,382,023
Balance ending Series D preferred stock (in shares) at Mar. 31, 2023																111.11
Balance ending at Mar. 31, 2023											$ 97			168,551,763	(167,180,877)		1,370,983
Balance ending (in shares) at Mar. 31, 2023											9,740,507
Balance beginning at Dec. 31, 2023								$ 4,677,632			$ 207			182,924,210	(202,761,017)		(15,158,968)
Balance beginning (in shares) at Dec. 31, 2023								319.76			20,744,110
Balance beginning Series D preferred stock at Dec. 31, 2023																$ 1,382,023	1,382,023
Balance beginning Series D preferred stock (in shares) at Dec. 31, 2023																111.11
Stock-based compensation														454,363			454,363
Exercise of warrants into common shares				$ 47,577,000	$ 47,577,000						$ 5			2,298,138			2,298,143
Exercise of warrants into common shares (in shares)				2,205.00							547,177
Conversion of preferred stock to common stock	$ 11	$ 3,972,529	$ 3,972,540			$ (1,203,346)	$ (33,983,571)		$ 9	$ 100		$ 1,203,337	$ 33,983,471
Conversion of preferred stock to common stock (in shares)	1,079,132					(82.26)	(1,575.00)		903,956	9,890,099
Retired shares (in shares)											(8)
Net loss															(26,641,983)		(26,641,983)
Balance ending Series D preferred stock at Mar. 31, 2024																$ 1,382,023	$ 1,382,023
Balance ending Series D preferred stock (in shares) at Mar. 31, 2024																111.11	111.11
Balance ending at Mar. 31, 2024								$ 17,067,715			$ 332			$ 224,836,048	$ (229,403,000)		$ 12,501,095
Balance ending (in shares) at Mar. 31, 2024								867.50			33,164,466